The clinical phenotype associated with anti-NXP2 antibodies is characterized by DM skin rash, calcinosis, periorbital oedema, severe myositis and dysphagia [2, 6, 8, 10–12], whilst controversial data regarding cancer association were reported [6, 12–15]. Here, MORC3 is linked to dermatomyositis.